Regentis is advancing GelrinC through a pivotal stage of development, with key catalysts including U.S. clinical study enrollment, European commercialization…
For a long time, scientists have wondered why many individuals that have several risk factors linked to cancer development never develop the disease while some…
Earth Science Tech, through its specialized subsidiaries, has created a vertically integrated healthcare platform that combines compounding pharmacy operations, telemedicine,…
Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) and may include paid advertising. As precision oncology becomes increasingly dependent on…
Regentis is targeting an estimated $3 billion U.S. cartilage repair market opportunity, supported by approximately 470,000 annual knee cartilage repair…
According to the findings of a recent poll conducted by Gallup and West Health, almost a quarter of employees within the U.S.,…
Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) and may include paid advertising. ONC010 is being developed for biomarker-selected cancers,…
The U.S. has recently had outbreaks of a number of infectious diseases, such as measles, mpox and HIV. These outbreaks have exposed critical gaps that exist…
The company has received Scientific Advice from Germany’s Paul-Ehrlich-Institute (“PEI”) supporting the proposed development strategy for its lead BiTAC(R)-TCE program.…
Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Quantum BioPharma’s MS focus is Lucid-MS, a patented…